Ranibizumab and the Risk of Arterial Thromboembolic Events

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
The investigators assume that ranibizumab might be dangerous in patients with history of coronary artery disease or cerebrovascular events. The main objective of study is to reveal contraindications for ranibizumab prescription in patients with history of coronary artery disease and cerebrovascular events. Moreover, an association between management with ranibizumab and ATE rate in healthy above 50 years old persons is a concern of great interest as well.
Epistemonikos ID: 89b2df6ee8966301bcfd667e9c4c410e13a53e69
First added on: May 06, 2024